| Spironolactone for heart failure with preserved ejection fraction B Pitt, MA Pfeffer, SF Assmann, R Boineau, IS Anand, B Claggett, ... New England Journal of Medicine 370 (15), 1383-1392, 2014 | 2802 | 2014 |
| Lixisenatide in patients with type 2 diabetes and acute coronary syndrome MA Pfeffer, B Claggett, R Diaz, K Dickstein, HC Gerstein, LV Køber, ... New England Journal of Medicine 373 (23), 2247-2257, 2015 | 2631 | 2015 |
| Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction SD Solomon, JJV McMurray, IS Anand, J Ge, CSP Lam, AP Maggioni, ... New England Journal of Medicine 381 (17), 1609-1620, 2019 | 2042 | 2019 |
| Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction SD Solomon, JJV McMurray, B Claggett, RA de Boer, D DeMets, ... New England Journal of Medicine 387 (12), 1089-1098, 2022 | 1749 | 2022 |
| Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial MA Pfeffer, B Claggett, SF Assmann, R Boineau, IS Anand, N Clausell, ... Circulation 131 (1), 34-42, 2015 | 1010 | 2015 |
| Impaired systolic function by strain imaging in heart failure with preserved ejection fraction E Kraigher-Krainer, AM Shah, DK Gupta, A Santos, B Claggett, B Pieske, ... Journal of the American College of Cardiology 63 (5), 447-456, 2014 | 884 | 2014 |
| Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis SB Seidelmann, B Claggett, S Cheng, M Henglin, A Shah, LM Steffen, ... The Lancet Public Health 3 (9), e419-e428, 2018 | 831 | 2018 |
| Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis H Uno, B Claggett, L Tian, E Inoue, P Gallo, T Miyata, D Schrag, ... Journal of clinical Oncology 32 (22), 2380-2385, 2014 | 691 | 2014 |
| SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials M Vaduganathan, KF Docherty, BL Claggett, PS Jhund, RA de Boer, ... The Lancet 400 (10354), 757-767, 2022 | 640 | 2022 |
| Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis … M Vaduganathan, BL Claggett, PS Jhund, JW Cunningham, JP Ferreira, ... The Lancet 396 (10244), 121-128, 2020 | 613 | 2020 |
| Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction SD Solomon, B Claggett, EF Lewis, A Desai, I Anand, NK Sweitzer, ... European heart journal 37 (5), 455-462, 2016 | 585 | 2016 |
| PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction SD Solomon, JJV McMurray, IS Anand, J Ge, CSP Lam, AP Maggioni, ... N Engl J Med 381 (17), 1609-1620, 2019 | 529 | 2019 |
| Declining risk of sudden death in heart failure L Shen, PS Jhund, MC Petrie, BL Claggett, S Barlera, JGF Cleland, ... New England Journal of Medicine 377 (1), 41-51, 2017 | 512 | 2017 |
| Heart failure with mid‐range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum LH Lund, B Claggett, J Liu, CS Lam, PS Jhund, GM Rosano, K Swedberg, ... European journal of heart failure 20 (8), 1230-1239, 2018 | 492 | 2018 |
| Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients AS Desai, JJV McMurray, M Packer, K Swedberg, JL Rouleau, F Chen, ... European heart journal 36 (30), 1990-1997, 2015 | 492 | 2015 |
| Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone AM Shah, B Claggett, NK Sweitzer, SJ Shah, IS Anand, L Liu, B Pitt, ... Circulation 132 (5), 402-414, 2015 | 490 | 2015 |
| Sacubitril/valsartan across the spectrum of ejection fraction in heart failure SD Solomon, M Vaduganathan, B L. Claggett, M Packer, M Zile, ... Circulation 141 (5), 352-361, 2020 | 482 | 2020 |
| Sex differences in blood pressure trajectories over the life course H Ji, A Kim, JE Ebinger, TJ Niiranen, BL Claggett, CNB Merz, S Cheng JAMA cardiology 5 (3), 255-262, 2020 | 427 | 2020 |
| Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial JP Seferovic, B Claggett, SB Seidelmann, EW Seely, M Packer, MR Zile, ... The lancet Diabetes & endocrinology 5 (5), 333-340, 2017 | 415 | 2017 |
| Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure K Damman, M Gori, B Claggett, PS Jhund, M Senni, MP Lefkowitz, ... JACC: Heart Failure 6 (6), 489-498, 2018 | 407 | 2018 |
Scott SolomonBrigham and Women's HospitalDirección de correo verificada de rics.bwh.harvard.edu